Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG8123 (GVAX) with/without cyclophosphamide in advanced NSCLC
NCT00089726Phase 2Completed
- Sponsor
- Cell Genesys
- Start
- Mar 2003
- Modality
- Bone Marrow HSCs, HLA-independent TCR-T, Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of CG8123 in non-small cell lung cancer (NSCLC), sponsored by Cell Genesys. Started Mar 2003; status: completed.
02
Drugs
CG8123
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00089726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089726.